Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy
Boda Guo,Feiya Yang,Lingpu Zhang,Qinxin Zhao,Wenkuan Wang,Lu Yin,Dong Chen,Mingshuai Wang,Sujun Han,Haihua Xiao,Nianzeng Xing
DOI: https://doi.org/10.1002/adma.202212267
IF: 29.4
2023-03-15
Advanced Materials
Abstract:Cuproptosis is a new cell death that depends on copper (Cu) ionophores to transport Cu into cancer cells, which induces cell death. However, existing Cu ionophores are small molecules with a short blood half‐life making it hard to transport enough Cu into cancer cells. Herein, a reactive oxygen species (ROS)‐sensitive polymer (PHPM) was designed, which was used to co‐encapsulate elesclomol (ES) and Cu to form nanoparticles (NP@ESCu). After entering cancer cells, ES and Cu, triggered by excessive intracellular ROS, were readily released. ES and Cu worked in a concerted way to not only kill cancer cells by cuproptosis, but also induce immune responses. In vitro, the ability of NP@ESCu to efficiently transport Cu and induce cuproptosis was investigated. In addition, the change in the transcriptomes of cancer cells treated with NP@ESCu was explored by RNA‐Seq. In vivo, NP@ESCu was found to induce cuproptosis in the mice model with subcutaneous bladder cancer, reprograming the tumor microenvironment. Additionally, NP@ESCu was further combined with anti‐programmed cell death protein ligand‐1 antibody (αPD‐L1). This study provides the first report of combining nanomedicine that can induce cuproptosis with αPD‐L1 for enhanced cancer therapy, thereby providing a novel strategy for future cancer therapy. This article is protected by copyright. All rights reserved
materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology